 |
Prospector
Profile
1109-01
|
| |
| Medicure, Inc. |
NAICS |
541710 |
| 4-1200 Waverley Street
Winnipeg, Manitoba, Canada R3T 0P4 |
Description |
Biotechnology |
| (204) 487-7412 |
Employees |
36 |
| http://www.medicure.com/ |
Revenue |
(mil) |
5.9440 |
| |
Income |
(mil) |
-31.7030 |
| |
Assets |
(mil) |
59.7850 |
| |
Liability |
(mil) |
34.3060 |
| |
(for the year ended 2007-05-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Medicure, Inc. reported a net loss of $31,703,386 on revenues of $5,944,730 for the year ended May 31, 2007, much higher than the net losses of $12,607,074 and $14,865,910 reported during the years ended May 31, 2006 and 2005, respectively. The Company also used cash for operating activities of $25,246,653 for the year ended May 31, 2007, compared to $12,678,498 during the previous fiscal year. As a result of its recurring losses, the Company showed an accumulated deficit of $77,830,952 in its May 31, 2007 balance sheet.
|
| |
|
Intellectual Property:
The Company owns or jointly owns 38 United States patents and has additional pending United States patent applications. [SEC Filing 20-F 08-27-07]
|
| |
|
Description:
The biopharmaceutical company engages in the discovery and development of therapeutics for cardiovascular needs.
|
| |
|
Officers:
Albert D. Friesen, Ph.D. (Chair, Pres. & CEO); Derek G. Reimer, CA (CFO); Jan-Ake Westin (VP); Brian Best (VP); Dawson J. Reimer, MAES (VP); Charles Gluchowski, Ph.D. (VP); Kishore Kapoor, CA (Dir.); Gerald P. McDole, MBA (Dir.); Arnold Naimark, M.D. (Dir.); Peter Quick (Dir.)
|
| |
|
Auditor:
KPMG LLP
|
| |
|
Securities:
Common Stock-Symbol MCU; AMEX;
116,314,509 common shares outstanding as of May 31, 2007.
|
| |
| |
| |
| return to main page |
|
|
